Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ritva Koskela"'
Autor:
Timo M. Blomster, Olli-Pekka Koivurova, Ritva Koskela, Karl-Heinz Herzig, Nicholas J. Talley, Jukka Ronkainen
Publikováno v:
BMC Public Health, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background The pathogenesis of inflammatory bowel disease (IBD) has not been fully elucidated. The aim of this study was to analyze the pregnancy period, perinatal period, and infancy period risk factors for IBD in a well-characterized birth
Externí odkaz:
https://doaj.org/article/a8a73fade98940688d07ac823efa58a6
Autor:
Tero Ylisaukko-oja, Clas-Göran af Björkesten, Anja Eberl, Heikki Nuutinen, Airi Jussila, Pauliina Molander, Ritva Koskela, Timo Blomster, Markku Pajala, Tuire Ilus, Paula Haiko, Bianca Kovac, Saija Silvola, Sarah Smith, Jari Jokelainen, Taina Sipponen
Publikováno v:
Heliyon, Vol 10, Iss 12, Pp e32432- (2024)
Purpose: To analyze treatment persistence and treatment outcomes of vedolizumab as first-line biological treatment in Crohn's disease (CD) and ulcerative colitis (UC) patients in a Finnish real-world setting. Methods: Observational, retrospective, mu
Externí odkaz:
https://doaj.org/article/e518e647233a4961aed70816ba0f7dab
Autor:
Tea Lamberg, Taina Sipponen, Sanna Valtanen, Kari K Eklund, Tarja Mälkönen, Kristiina Aalto, Katriina Mikola, Kaija-Leena Kolho, Sanna Leinonen, Pia Isomäki, Heidi Mäkinen, Krista-Liisa Vidqvist, Arto Kokko, Laura Huilaja, Minna Kyllönen, Paula Keskitalo, Sirja Sard, Paula Vähäsalo, Ritva Koskela, Liisa Kröger, Perttu Lahtinen, Anna-Maija Haapala, Katja Korkatti, Tuulikki Sokka-Isler, T. Sakari Jokiranta
Publikováno v:
Autoimmunity, Vol 55, Iss 5, Pp 275-284 (2022)
Introduction The prevalence of immune-mediated diseases has increased in the past decades and despite the use of biological treatments all patients do not achieve remission. The aim of this study was to characterise the reasons for short interruption
Externí odkaz:
https://doaj.org/article/d471061e9b8a414b9021f87dde85a9bf
Autor:
Janne Hukkanen, Henri Lumme, Olli Kettunen, Kari Syrjänen, Timo Blomster, Jukka Ronkainen, Markus J. Mäkinen, Antti Ala-Rämi, Ritva Koskela, Tuomo J. Karttunen, Olli-Pekka Koivurova
Publikováno v:
Anticancer Research. 41:5527-5537
BACKGROUND/AIM Prompted by the increasing demand of non-invasive diagnostic tools for screening of gastric cancer (GC) risk conditions, i.e., atrophic gastritis (AG) and Helicobacter pylori (Hp) infection, the GastroPanel® test (GP: biomarker panel
Autor:
Ritva Koskela, Clas-Göran af Björkesten, Jyrki Tillonen, Christian Nielsen, M Koivunen, Erkki Soini, Taru Hallinen, Ilkka Vihriälä, Airi Jussila, Ulla-Maija Suhonen, C Wennerström, Karri T Utriainen, Inka Koskinen, Kalle Hakala, R Nissinen, Tuire Ilus, Andras Borsi, Heikki Nuutinen, Markku Heikkinen, Veikko Moilanen, Taina Sipponen, Urpo Nieminen, Anja Eberl, Mikko Heikura
Publikováno v:
European Journal of Gastroenterology & Hepatology
Objective: Long-term evidence on ustekinumab treatment response and persistence in patients with Crohn’s disease in a real-world setting is scarce. We performed a retrospective nationwide chart review study of long-term clinical outcomes in Crohn
Autor:
Olli-Pekka, Koivurova, Ritva, Koskela, Timo, Blomster, Antti, Ala-Rämi, Henri, Lumme, Olli, Kettunen, Janne, Hukkanen, Tuomo J, Karttunen, Markus, Mäkinen, Jukka, Ronkainen, Kari, Syrjänen
Publikováno v:
Anticancer research. 41(11)
Prompted by the increasing demand of non-invasive diagnostic tools for screening of gastric cancer (GC) risk conditions, i.e., atrophic gastritis (AG) and Helicobacter pylori (Hp) infection, the GastroPanelAltogether, 522 patients were enrolled among
Autor:
Jyrki Tillonen, Ritva Koskela, M Koivunen, Ulla Maija Suhonen, Mikko Heikura, Christian Nielsen, Anja Eberl, Taru Hallinen, E Christina M Wennerström, Mikko Kellokumpu, Heikki Nuutinen, Markku Heikkinen, Erkki Soini, Tuire Ilus, Andras Borsi, Clas Göran af Björkesten, Taina Sipponen
Publikováno v:
Scandinavian journal of gastroenterology. 56(6)
Background: Real-world evidence to support optimal ustekinumab dosing for refractory Crohn’s disease (CD) patients remains limited. Data from a retrospective nationwide chart review study was utilized to explore ustekinumab dosing dynamics and opti
Autor:
Ritva Koskela, Jennifer Hollis, Frank M. Ruemmele, Giuseppe Castaldo, Lorenzo Norsa, Giusi Grimaldi, Emeline Bequet, Peter Heinz-Erian, Holm H. Uhlig, Saara Leskinen, Remi Duclaux-Loras, Simon Travis, Alain Lachaux, Roberto Berni Canani, Kaija-Leena Kolho, Astor Rodrigues, Lukasz Dembinski, Jaques Deflandre, Neil Shah, Richard K. Russell, Andreas R. Janecke, Satu Wedenoja, Jutta Köglmeier, Sibylle Koletzko
Publikováno v:
Journal of Crohn'scolitis. 15(10)
Background Congenital chloride diarrhoea [CLD] is a rare autosomal recessive disease caused by mutations in the solute family carrier 26 member 3 [SLC26A3] gene. Patients suffer from life-long watery diarrhoea and chloride loss. Inflammatory bowel di
Autor:
Kalle Hakala, C Wennerström, Eija Hirsi, Moilanen, Mikko Heikura, Ilkka Vihriälä, Jyrki Tillonen, C G af Björkesten, Karri T Utriainen, Taru Hallinen, Urpo Nieminen, Heikki Nuutinen, Tuire Ilus, Ulla-Maija Suhonen, Erkki Soini, Ritva Koskela, Mikko Kellokumpu, Airi Jussila, Christian Nielsen, Anja Eberl, Inka Koskinen, Andras Borsi, R Nissinen, Taina Sipponen, Markku Heikkinen, M Koivunen
Publikováno v:
Journal of Crohn's and Colitis. 14:S434-S435
Background Real-life long-term evidence on ustekinumab treatment response in patients with Crohn’s disease (CD) is scarce. We performed a retrospective non-interventional nationwide chart review study of dosing and long-term clinical outcomes in Fi
Autor:
Ritva Koskela, Mikko Kellokumpu, Mikko Heikura, Taru Hallinen, Christian Nielsen, C Wennerström, Urpo Nieminen, M Koivunen, Inka Koskinen, Ilkka Vihriälä, C G af Björkesten, Kalle Hakala, Eija Hirsi, Anja Eberl, Erkki Soini, Jyrki Tillonen, R Nissinen, Ulla-Maija Suhonen, Taina Sipponen, Tuire Ilus, Veikko Moilanen, Andras Borsi, Heikki Nuutinen, Markku Heikkinen, Karri T Utriainen, Airi Jussila
Publikováno v:
Journal of Crohn's and Colitis. 14:S066-S066
Background Real-life long-term evidence on ustekinumab treatment in patients with Crohn’s disease (CD) is limited. We performed a retrospective non-interventional nation-wide chart review study of dosing and long-term clinical outcomes in Finnish C